Molecular pathology: about KRAS genotyping in colorectal carcinomas;Pathologie moléculaire tumorale : à propos du génotypage de KRAS dans les carcinomes colorectaux

Revue Francophone des Laboratoires

Volumn 2010, Issue 418, 2010, Pages 43-46

  Sabourin, Jean Christophe ^a,b   Lamy, Aude ^a,b   Le Pessot, Florence ^a,b   Sesboüé, Richard ^b   Frébourg, Thierry ^b  

^a HÔPITAL CHARLES NICOLLE   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

KRAS genotyping; metastatic colorectal carcinoma; molecular pathology; pathology

Indexed keywords

EID: 77249127422     PISSN: 1773035X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-035X(10)70344-0     Document Type: Article

References (10)

1. Bibeau F., Penault-Llorca F., and Sabourin J.C. Détection des mutations de KRAS : évolution ou révolution pour les pathologistes?. Ann Pathol 28 4 (2008) 261-262
2. Bouali S., Chretien A.S., Ramacci C., Rouyer M., Becuwe P., and Merlin J.L. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 21 3 (2009) 731-735
3. Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009l;16(4):196-203.
4. Loupakis F., Ruzzo A., Cremolini C., Vincenzi B., Salvatore L., Santini D., et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101 4 (2009) 715-721
5. Di Fiore F., Blanchard F., Charbonnier F., Le Pessot F., Lamy A., Galais M.P., et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96 8 (2007) 1166-1169
6. Lievre A., Bachet J.B., Boige V., Cayre A., Le C.D., Buc E., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 3 (2008) 374-379
7. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26 35 (2008) 5705-5712
8. Preto A., Figueiredo J., Velho S., Ribeiro A.S., Soares P., Oliveira C., et al. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. J Pathol 214 3 (2008) 320-327
9. Marchetti A., Felicioni L., and Buttitta F. Assessing EGFR mutations. N Engl J Med 354 5 (2006) 526-528
10. Di Fiore F., Charbonnier F., Lefebure B., Laurent M., Le Pessot F., Michel P., et al. Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer 99 3 (2008) 551-552